Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double‐blind placebo‐controlled clinical trial
Clinical & Experimental Allergy · 2023
DOI: 10.1111/cea.14307 ↗At a glance
Randomisierte kontrollierte Studie in Clinical & Experimental Allergy, 2023. Written by Lars Ahlbeck and 8 co-authors. Institution: Allergy Center, University Hospital, Linköping, Sweden. Major MEDLINE topics: Rhinitis, Allergic, Seasonal. Cited 15 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: Västra Götalandsregionen.
Abstract (original language)
Introduction
There is a need to evaluate the safety and efficacy of intralymphatic immunotherapy (ILIT) for inducing tolerance in patients with allergic rhinitis.
Methods
Thirty‐seven patients with seasonal allergic symptoms to birch and grass pollen and skin prick test >3 mm and/or IgE to birch and timothy >0.35 kU/L were randomized to either ILIT, with three doses of 0.1 mL of birch pollen and 5‐grass pollen allergen extracts on aluminium hydroxide (10,000 SQ‐U/ml; ALK‐Abelló) or placebo using ultrasound‐guided intralymphatic injections at monthly intervals. Daily combined symptom medical score and rhinoconjunctivitis total symptom score were recorded during the peak pollen seasons the year before and after treatment. Rhinoconjunctivitis total symptom score, medication score and rhinoconjunctivitis quality of life questionnaire were recorded annually starting 2 years after treatment. Circulating proportions of T helper cell subsets and allergen‐induced cytokine and chemokine production were analysed using flow cytometry and ELISA.
Results
There were no differences between the groups related to daily combined symptom medical score the year before and after treatment. Two years after ILIT (after unblinding), the actively treated group reported significantly fewer symptoms, lower medication use and improved quality of life than did the placebo group. After the pollen seasons the year after ILIT, T regulatory cell frequencies and grass‐induced IFN‐γ levels increased only in the actively treated group.
Conclusion
In this randomized controlled trial, ILIT with birch and grass pollen extract was safe and accompanied by immunological changes. Further studies are required to confirm or refute the efficacy of the treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Allergy Center, University Hospital, Linköping, Sweden.
- Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- Futurum, Academy of Health and Care, Jönköping, Sweden.
- Department of Biomedical and Clinical Sciences, Division of Children's and Women's Health, Linköping University, Linköping, Sweden.
ORCID profiles: Lars Ahlbeck
Funding
- Västra Götalandsregionen
Cite
APA
Ahlbeck, L., Ahlberg, E., Stuivers, L., Björkander, J., Nyström, U., Retsas, P., Govindaraj, D., Jenmalm, M. C., & Duchén, K. (2023). Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double‐blind placebo‐controlled clinical trial. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14307
Vancouver
Ahlbeck L, Ahlberg E, Stuivers L, Björkander J, Nyström U, Retsas P, et al. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double‐blind placebo‐controlled clinical trial. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14307
BibTeX
@article{Ahlbeck2023,
author = {Ahlbeck, Lars and Ahlberg, Emelie and Stuivers, Linn and Björkander, Janne and Nyström, Ulla and Retsas, Pavlos and Govindaraj, Dhanapal and Jenmalm, Maria C and Duchén, Karel},
title = {Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double‐blind placebo‐controlled clinical trial},
journal = {Clinical & Experimental Allergy},
year = {2023},
doi = {10.1111/cea.14307}
}
EUVIMED